Lee Ainslie Verona Pharma PLC Call Options Transaction History
Maverick Capital LTD
- $5.17 Billion
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding VRNA
# of Institutions
218Shares Held
70.5MCall Options Held
1.4MPut Options Held
299K-
Perceptive Advisors LLC New York, NY6.39MShares$445 Million9.9% of portfolio
-
Nea Management Company, LLC Timonium, MD5.58MShares$389 Million18.53% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.38MShares$236 Million9.42% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.13MShares$218 Million2.79% of portfolio
-
Wellington Management Group LLP Boston, MA3.03MShares$211 Million0.03% of portfolio
About Verona Pharma plc
- Ticker VRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,954,200
- Market Cap $4.24B
- Description
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...